Latest Property Portfolio News

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

BluGlass Limited reported a 16% rise in revenue to $11.7 million for FY25, driven by key US Department of Defense contracts and new partnerships. However, the company’s net loss increased 8% to nearly $11 million amid ongoing R&D investment and operational scaling.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

CVC Limited has reversed its fortunes with a $0.5 million net profit after tax for FY25, driven by strong property investment income and strategic land developments, while maintaining a cautious capital management approach and withholding dividends.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Scentre Group reported a 93% surge in half-year profit to $782.2 million, driven by strong operational growth and property valuation gains. The Group declared an interim distribution of 8.815 cents per security and reaffirmed its 2025 growth guidance.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

K&S Corporation reported a 9% decline in underlying profit before tax for FY2025, alongside a 9.7% drop in revenue, as it invests heavily in property and terminal upgrades while navigating safety regulatory pressures.

Clime Capital Limited reported a 29% drop in net profit for FY25 but maintained its quarterly dividends and rolled over convertible notes with enhanced terms. The company is pivoting towards a debt-focused portfolio to boost income stability.